I first wrote about Santarus
Often after approval, investors can breathe a sigh of relief and enjoy a relatively calm period while sales ramp up. That is not necessarily the case here, as Santarus has to tackle the challenge of penetrating a market with very stiff competition. The market contains such drug titans as AstraZeneca's
As a small company, Santarus is definitely going to have its hands full marketing Rapinex against such well-known players. That being said, the firm's marketing strategy certainly seems reasonable. Between now and the fourth quarter, the company is going to hire and train 230 sales reps and unleash them on the group of physicians that writes the most prescriptions for this class of drugs. That's a common-sense approach employed by many small drug companies to help get the most bang for the marketing buck.
While success is never guaranteed in the drug industry, the next 18 months should, at the very least, be interesting. During this time, the company will hear whether the FDA will OK the 40 mg dose of Rapinex, and the company will also conduct late-stage trials for capsule and chewable tablet formulations.
I think the knee-jerk reaction amongst investors is that small drug companies cannot compete head to head against large pharma. We will find out soon enough if that conventional wisdom is correct.
To read more by Charly on the exciting biotech industry, check out his recent articles:
Fool contributor Charly Travers owns shares of Santarus, but no other companies mentioned.
More from The Motley Fool
Airbus Sets a Monthly Order Record for December
The aerospace titan finalized more than twice as many airplane orders last month as it did in the rest of 2017.
1 Dividend Stock to Buy and Hold for Life
Starbucks may no longer be the growth engine it once was, but it’s still a solid choice for investors in search of a stable business with attractive dividend prospects.
Want to Mine Ripple? Think Again
Not all cryptocurrencies work the same.